المؤلفون: Roberto M., Botticelli A., Panebianco M., Aschelter A. M., Gelibter A., Ciccarese C., Minelli M., Nuti M., Santini D., Laghi A., Tomao S., Marchetti P.

المساهمون: Roberto, M., Botticelli, A., Panebianco, M., Aschelter, A. M., Gelibter, A., Ciccarese, C., Minelli, M., Nuti, M., Santini, D., Laghi, A., Tomao, S., Marchetti, P.

مصطلحات موضوعية: immune checkpoints inhibitor, new biomarker, renal cancer carcinoma, targeted therapy, tyrosine kinase inhibitor (TKI)

العلاقة: info:eu-repo/semantics/altIdentifier/pmid/33968762; info:eu-repo/semantics/altIdentifier/wos/WOS:000647553300001; volume:11; journal:FRONTIERS IN ONCOLOGY; http://hdl.handle.net/11573/1580778Test; info:eu-repo/semantics/altIdentifier/scopus/2-s2.0-85105470539

الإتاحة: https://doi.org/10.3389/fonc.2021.657639Test
http://hdl.handle.net/11573/1580778Test

المؤلفون: Michela Roberto, Andrea Botticelli, Martina Panebianco, Anna Maria Aschelter, Alain Gelibter, Chiara Ciccarese, Mauro Minelli, Marianna Nuti, Daniele Santini, Andrea Laghi, Silverio Tomao, Paolo Marchetti

المصدر: Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)

مصطلحات موضوعية: Oncology, Cancer Research, medicine.medical_specialty, medicine.medical_treatment, Immune checkpoint inhibitors, tyrosine kinase inhibitor (TKI), immune checkpoints inhibitor, Review, Targeted therapy, Immune system, Renal cell carcinoma, Internal medicine, medicine, RC254-282, business.industry, renal cancer carcinoma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, new biomarkers, medicine.disease, targeted therapy, Clinical Practice, Clinical trial, Cancer cell, Molecular mechanism, business

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4fd53cd43b664f5c464953c79e21a24cTest
http://hdl.handle.net/11573/1580778Test